Press Releases
Jeremiah Smith Appointed to Sierra College Foundation Board of Directors
DIXON, Calif.--(BUSINESS WIRE)--First Northern Bank is proud to announce that President and Chief Executive Officer Jeremiah Smith has been appointed to the Board of Directors of the Sierra College Foundation. The Sierra College Foundation supports student success and educational advancement through scholarships, programs, and community partnerships that help create opportunities for students throughout the region. As a member of the Board of Directors, Smith will help support the Foundation's...
Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M
Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquartered in Tulsa, Oklahoma. The Agreement grants Fission exclusive worldwide rights to import, market, distribute, and sell HBC's ProGo salmon-derived bioactive peptide ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel...
Carolina Financial Services Group Tackles Retirement's “Double Threat”: How Tax and Healthcare Risks Impact Retirees
Greenville, NC, May 21, 2026 (GLOBE NEWSWIRE) -- Carolina Financial Services Group, a Registered Investment Advisor firm with more than 30 years of experience in the Greenville and eastern North Carolina region as well as in the entire East Coast, is addressing the critical need for retirees to mitigate taxation and healthcare costs through a specialized, tech-enabled planning process...
Swiss Water Reports Voting Results from Annual General and Special Meeting of Shareholders
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Swiss Water Decaffeinated Coffee Inc. (TSX : SWP) (“Swiss Water” or “the Company”), a leading specialty coffee company and premium green coffee decaffeinator, is pleased to announce the following voting results of the Company's Annual General and Special Meeting of Shareholders, which was held on Thursday, May 21, 2026...
Licensing Expo Concludes with Record-Breaking Show Floor and Participation from Cultural Icons, Cementing Status as Global Epicenter for Brand Collaboration
LAS VEGAS, May 21, 2026 (GLOBE NEWSWIRE) -- Informa Markets' Licensing Expo , the world's most influential event for licensing, IP extension, and brand collaborations, concluded today following three days of unparalleled industry activity at the Mandalay Bay Convention Center. The 2026 edition delivered the largest number of exhibiting companies on record, with 410 exhibitors representing more than 5,000 brands and drawing registered professionals from across the global licensing ecosystem...
VVC Exploration Corporation Provides Regulatory Update and Clarifies a Previous Incorrect Statement about CYRB
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- VVC Exploration Corporation, dba VVC Resources (“VVC” or the “Company”) (TSX-V: VVC and OTCQB: VVCVF) is providing an update to its previous news release dated May 16, 2026, regarding the status of its annual financial filings. The Ontario Securities Commission (the "OSC") has notified the Company that its application for a Management Cease Trade Order ("MCTO") has been rejected...
Silverco Mining Files NI 43-101 Technical Report for the Cusi Project PEA
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Silverco Mining Ltd. (TSXV: SICO) (OTCQB: SICOF) ("Silverco" or the "Company") announces that, in connection with its news release dated April 13, 2026, it has filed on SEDAR+ a National Instrument 43-101 Technical Report titled "Preliminary Economic Assessment Cusi Project, Chihuahua, Mexico" (the "Technical Report"), with an effective date of March 31, 2026...
American Hotel Income Properties REIT LP Announces Annual and Special Meeting of Unitholders
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- American Hotel Income Properties REIT LP (“AHIP”, or the “Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB. V) announced today that the board of directors of AHIP's general partner (the “Board”) has called an annual and special meeting of unitholders of AHIP (“Unitholders”) to be held on June 18, 2026 (the “Meeting”). The information circular and voting-related materials for the Meeting are being mailed to Unitholders and are also available under AHIP's profile on SEDAR+ at www.sedarplus.ca and on AHIP's website at https://www.ahipreit.com...
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
TORONTO, ON / ACCESS Newswire / May 21, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce the voting results from its annual general and special meeting of shareholders held today (the "Meeting"). At the Meeting, shareholders approved all matters brought before the Meeting, including matters relating to the Company's previously announced proposed amalgamation transaction involving Psyence Therapeutics Corp., a wholly owned subsidiary of the Company, and GoldCoast Resource Corp. ("GoldCoast") (the "Transaction")...
ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
HERNDON, Va., May 21, 2026 /PRNewswire/ -- ePlus inc.
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline...
What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors
WELLESLEY, Mass., May 21, 2026 /PRNewswire/ -- Sun Life U.S. has released its annual High-Cost Claims and Injectable Drug Trends report, which analyzed over 70,000 high-dollar medical claims from more than 3,300 self-funded employers across the country.
As U.S. Markets Continue Roaring to Historic All-Time Highs Like Eagles Above Wall Street, ELEKTROS Celebrates Growing Momentum and Rising Global Awareness Among Penny Stock and Microcap Investors Discovering the Company's Vision for Lithium Mining and Revolutionary EV Patent Technology
WEST PALM BEACH, FL / ACCESS Newswire / May 21, 2026 / As U.S. stock markets continue reaching historic all-time highs and investor appetite for next-generation energy and technology opportunities accelerates across Wall Street, ELEKTROS Inc. (Ticker Symbol:ELEK) announced today that the Company continues aggressively advancing its lithium mining initiatives, electric vehicle charging patent strategy, and broader electrification-focused growth initiatives. Management believes the electrification revolution is accelerating worldwide as lithium demand, EV adoption, and next-generation charging infrastructure continue expanding across global markets...
Credissential Announces Private Placement
CALGARY, AB / ACCESS Newswire / May 21, 2026 / Credissential Inc. ("Credissential" or the "Company") (CSE:WHIP), a vertically integrated AI software development company is pleased to announce a non-brokered private placement financing of up to 3,000,000 units of the Company (the "Units") at a price of $0.16 per Unit for gross proceeds of up to $480,000 (the "Offering"). Each Unit will consist of one common share in the capital of the Company (a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant")...
Midland Exploration Completes a $5.3 Million Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 21, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland” or “Corporation”) (TSX-V: MD) is pleased to announce that it has completed a second and final tranche of its previously announced non-brokered private placement by issuing 6,926,123 units of Midland at a price of $0.45 per unit for aggregate gross proceeds of $3.1 million. Each unit consists of one common share and one warrant...
Lightmatter Unveils Guide DR: Industry First Liquid-Cooled Laser NIC that Quadruples Rack Density
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Lightmatter, the leader in photonic (super)computing, today announced Guide DR, a high-density laser in an innovative Laser Network Interface Card (“LNIC”) form factor built to OCP NIC 3.0 dimensions. The Guide DR LNIC is a modular, high-density laser array that enables approximately four times the rack density of conventional External Laser Small Form Factor Pluggables (ELSFPs). By relocating the light source from the faceplate into the chassis, the Gui...
Promino Announces Closing of Final Tranche of Private Placement
Burlington, Ontario--(Newsfile Corp. - May 21, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition company focused on clinically validated amino acid formulations, announces that, further to its press releases dated March 13, April 22, May 5, May 15 and May 20, 2026, the Company has closed its final tranche (the "Final Tranche") of its private placement, issuing an aggregate of 3,000,000 units ("Units") at a price of $0.03 per Unit for gross proceeds of $90,000. The Units are composed of one (1) Share and one half of one (1/2) Share purchase warrant, each whole warrant exercisable into one (1) additional Share at a price of $0.06 for one (1) year from the date of issuance...
America's Uranium Corp. Announces Strategic Engagement of Axiom Group and Technical Advisor to Leverage New Geophysical Assessment Results in Ford Lake, Saskatchewan
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Americas Uranium Corp. (CSE: NUCA) (OTC Pink: ASRFF) (the "Company" or "Americas Uranium") is pleased to announce the advancement in its exploration strategy for the Ford Lake Uranium Project (the "Ford Lake Project") located on the south-eastern edge of the world-renowned Athabasca Basin, Saskatchewan. The company has received a comprehensive geophysical assessment report for the Ford Lake Project, defining high priority structural targets...
PlasCred Circular Innovations Inc. Announces Closing of Second Tranche of Upsized Non-Brokered Private Placement Under Listed Issuer Financing Exemption
Calgary, Alberta--(Newsfile Corp. - May 21, 2026) - PlasCred Circular Innovations Inc. (CSE: PLAS) (FSE: XV2) ("PlasCred" or the "Company") is pleased to announce that, as a result of strong investor demand, it has closed the second tranche (the "Second Tranche") of its previously announced upsized non-brokered $7,000,000 private placement (the "Offering"), issuing 9,746,000 units of the Company (each, a "Unit") at a price of $0.17 per Unit for aggregate gross proceeds of $$1,656,820, pursuant to the listed issuer financing exemption of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"). Proceeds from the Offering will be used to advance development of the Company's advanced plastic recycling commercial facility ("Neos"), to be located at CN Rail's Scotford Yard in Alberta's Industrial Heartland, including detailed engineering, permitting, procurement of long-lead equipment, and also for general working capital...
Zai Lab Announces Changes to Senior Leadership Team
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors,"...
CORRECTION – Canadian Banc Corp. Monthly Dividend Declaration for Class A & Preferred Share
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- In a prior communication disseminated on May 21, 2026 regarding the May 29, 2026 dividend declaration for BK Class A Shares, the VWAP used to determine the payment rate was not adjusted for the May 19, 2026 Class A Share Split (1.1 for 1). Accordingly, the final dividend payable for the May 29, 2026 record date is $0.16900 per BK Class A Share, revised from the previously disclosed $0.18588. The payment rate is based on 15% of the adjusted VWAP for the last three trading days of the preceding month. The total distributions to date were impacted and have also been amended. No other changes have been made. The corrected release follows:
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson's disease. Results from the study show that BIIB122 did not slow the progression of Parkinson's disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant...
St. Augustine Gold and Copper Limited Announces Board and Management Changes
Manila, Philippines--(Newsfile Corp. - May 21, 2026) - St. Augustine Gold and Copper Limited (TSX: SAU) ("St. Augustine" or the "Company") announces the resignation of Mr. Nicolaos Paraskevas from its board of directors effective May 17, 2026.
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Prairie Provident Reports on AGM Voting Results
CALGARY, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces voting results from its annual and special shareholders' meeting held today (the “Meeting”). A total of 39,148,743 common shares, representing approximately 83.8% of the Company's issued and outstanding common shares, were represented in person or by proxy at the Meeting...
iwon(TM) Podcast Launches to Challenge the 'Overnight Success' Narrative in SaaS and Tech
London, United Kingdom--(Newsfile Corp. - May 21, 2026) - Michael J. Thomas, founder of DARWIN™ Works Marketing, has launched the iwon™ podcast (It Wasn't Over Night), a long-form series focused on the reality of building software and technology companies beyond the polished success stories often seen online...
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, IL...
M&T Bank Corporation to Participate in the Morgan Stanley US Financials Conference
BUFFALO, N.Y., May 21, 2026 /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE:MTB) will participate in the Morgan Stanley US Financials Conference being held in New York City.
As U.S. Markets Continue Soaring Like Eagles Across Record-Breaking All-Time Highs, ELEKTROS Gains Momentum - Closing Higher Today as Growing Numbers of Penny Stock and Microcap Investors Discover the Company's Vision for Lithium Mining and Advanced EV Patent Technology
WEST PALM BEACH, FL / ACCESS Newswire / May 21, 2026 / As U.S. stock markets continue reaching historic all-time highs and investor appetite for next-generation energy and technology opportunities accelerates across Wall Street, ELEKTROS Inc. (Ticker Symbol:ELEK) announced today that the Company continues aggressively advancing its lithium mining initiatives, electric vehicle charging patent strategy, and broader electrification-focused growth initiatives. Management believes the electrification revolution is accelerating worldwide as lithium demand, EV adoption, and next-generation charging infrastructure continue expanding across global markets...
Conduent Announces Agreement to Sell Its Public Transit Business to Modaxo for $164 Million
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Conduent Incorporated (Nasdaq: CNDT), a global technology‑driven business solutions and services provider, today announced that it has entered into a definitive agreement to sell its Public Transit business, an operating unit of Conduent Transportation, to Modaxo, a global technology organization focused on moving the world's people. The Public Transit business consists of Transit Fare Management and Fleet Management Solutions businesses. The sale has a purc...
Halliburton Announces Dividend
HOUSTON--(BUSINESS WIRE)--Halliburton Company (NYSE: HAL) announced today that its board of directors has declared a 2026 second quarter dividend of seventeen cents ($0.17) a share on the Company's common stock payable on June 24, 2026, to shareholders of record at the close of business on June 3, 2026. About Halliburton Halliburton is one of the world's leading providers of products and services to the energy industry. Founded in 1919, we create innovative technologies, products, and services...
FCPT Announces Acquisition of a Gerber Collision Property for $3.5 Million
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Gerber Collision property for $3.5 million. The property is located in a highly trafficked corridor in North Carolina and corporate-operated under a triple net lease with approximately eight years of term r...
MSCI Announces Dates for 2026 Annual Market Classification and Accessibility Reviews
NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it will release the results of the MSCI 2026 Global Market Accessibility Review on June 18, 2026, and the results of the MSCI 2026 Annual Market Classification Review on June 23, 2026. Both announcements will be made available shortly after 10:30 p.m. Central European Summer Time (CEST) on www.msci.com/market-classificati...
CanCambria Energy Announces Participation in 2026 Louisiana Energy Conference
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - CanCambria Energy Corp. (TSXV: CCEC) (FSE: 4JH) (OTCQB: CCEYF) ("CanCambria" or the "Company") announced today that it will participate in the 2026 Louisiana Energy Conference hosted by Al Petrie Advisors, to be held in New Orleans, Louisiana, on May 26-28, 2026, at the Four Seasons Hotel. Dr. Paul Clarke, Chief Executive Officer, will participate in an International E&P panel discussion on Wednesday, May 27, 2026, at 3:00 p.m...
Modaxo Enters into Agreement to Acquire the Public Transit Business from Conduent
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Modaxo Inc. (“Modaxo”), a global technology organization focused on moving the world's people, today announced that it has signed a definitive agreement to acquire the Public Transit Business, consisting of Transit Fare Management and Fleet Management Solutions businesses, from Conduent Incorporated. Completion of the acquisition remains subject to closing conditions...
nVent to Participate in Upcoming Investor Conference
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST...
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. The poster, titled "Azenosertib Plus Paclitaxel for Platinum-Resistant Ovarian Cancer: Results From a Phase 1b Study," will be presented in the Gynecologic Cancer Poster Session (Abstract #5529, Poster Board #195) on June 1, 2026, from 9:00am–12:00pm CDT...
Manulife Announces Executive Leadership Team Changes
Changes Include Canada Segment, Hong Kong, AI and Data, and Technology and Operations New Team Structure Enables Execution Against Strategic Priorities for Long-term Growth TORONTO, May 21, 2026 /PRNewswire/ - Manulife has announced changes to its executive and senior leadership teams across Canada, Hong Kong, AI and Data, and Technology and Operations to enable sustainable, long-term growth as the company executes its refreshed enterprise strategy. "These important leadership changes ensure we have the right capabilities, both at the enterprise level and in our key markets of Canada and Hong Kong, to achieve our bold ambition and deliver against our new strategic priorities," said Phil Witherington, President and CEO of Manulife...
New Lockheed Martin Facility to Support America's Arsenal of Freedom, Accelerated Production of THAAD Interceptors
Department of War and state officials celebrate groundbreaking in Alabama today TROY, Ala., May 21, 2026 /PRNewswire/ -- Today, Lockheed Martin broke ground on a new Munitions Production Center in Troy, Alabama, marking its latest investment to expand munitions production for the United States and its allies...
Amex Exploration Raises C$59 Million in Total as it Closes Second Tranche of Private Placement
Montreal, Quebec--(Newsfile Corp. - May 21, 2026) - Amex Exploration Inc. (TSXV: AMX) (FSE: MX0) (OTCQX: AMXEF) ("Amex" or the "Company") is pleased to announce that, further to the Company's news release of earlier today, it has closed its non-brokered private placement of 1,622,222 common shares of the Company (the "Common Shares") at a price of $4.50 per Common Share (the "Offering Price") for gross proceeds of C$7,299,999 (the "Non-Brokered Private Placement"). Together with closing earlier today of the Company's "best efforts" private placement of 11,504,161 Common Shares at the Offering Price (the "Brokered Private Placement"), the Company raised aggregate gross proceeds of C$59,068,723.50...
BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO
BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer...
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago...
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026...
VCI Global Received NASDAQ Notice Related to Late Filing of 20-F
KUALA LUMPUR, Malaysia, May 21, 2026 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that it received a notification letter from the Nasdaq Stock Market LLC (“NASDAQ”) on May 19, 2026 regarding the delayed filing of the Company's Form 20-F for the financial year ended December 31, 2025...
Integrated Quantum Technologies Announces Refiling of MD&A
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Integrated Cyber Solutions Inc. (CSE: ICS) (OTCQB: IGCRF) (FSE: Y4G), doing business as Integrated Quantum Technologies ("Integrated Quantum" or the "Company"), announces that as result of a continuous disclosure review by the BC Securities Commission, the company has refiled its management's discussion and analysis ("MD&A") for the period ended December 31, 2025. The revised MD&A includes, amongst other items, clarifying disclosure on the Company's validation and testing activities relating to AIQu™/Veil™, and related expenditures...
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA submission and ongoing investigation in Phase 3 ALKAZAR trial for TKI-naïve patients with advanced ALK-positive NSCLC First presentation of encouraging preliminary data for zidesamtinib in patients with advanced ROS1-positive solid tumors other than NSCLC from ARROS-1 trial CAMBRIDGE, Mass., May 21, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global, single-arm ALKOVE-1 Phase 1/2 clinical trial, and preliminary data in patients with advanced ROS1-positive solid tumors other than NSCLC from the global, single-arm ARROS-1 Phase 1/2 clinical trial of zidesamtinib, an investigational ROS1-selective inhibitor, to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago...
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago...
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster session Real-world data further supports the use of REZLIDHIA (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclax SOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO (pralsetinib) as first-line treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 29, 2026...
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering")...
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT...
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois...
Equus Announces First Quarter Net Asset Value
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of March 31, 2026, of $20.9 million. Net asset value per share increased to $1.50 as of March 31, 2026, from $1.19 as of December 31, 2025.
Logitech Files Annual Report on Form 10-K
LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it filed its Annual Report on Form 10-K for Fiscal Year 2026, which ended March 31, 2026, with the U.S. Securities and Exchange Commission. It is available on Logitech's website at http://ir.logitech.com. Logitech expects to publish its annual report to shareholders, and its invitation and proxy statemen...
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif...
North American Construction Group Ltd. Announces Voting Results of Annual and Special Meeting of Shareholders
ACHESON, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA/NYSE:NOA) today announced the results of its Annual and Special Meeting of Shareholders held on May 20, 2026. Shareholders elected directors, approved the appointment of KPMG LLP as the independent auditors of the Company, approved a non-binding advisory vote regarding the Company's approach to executive compensation and ratified an Advance Notice Bylaw. The following are the results of the votes held at the meeting:
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs...
Cleantek Industries Inc. First Quarter 2026 Interim Update
Calgary, Alberta--(Newsfile Corp. - May 21, 2026) - Cleantek Industries Inc. (TSXV: CTEK) ("Cleantek" or the "Company"), a leading provider of patented energy technology solutions that reduce cost and carbon intensity in the wastewater management and industrial lighting sectors, is pleased to provide a business update and unaudited financial highlights for the three months ended March 31, 2026. During the quarter, the Company increased investments in strategic growth initiatives and upcoming projects expected to drive future revenue growth, including expenditures tied to its previously announced large international HALO SE project scheduled to commence in Q2 2026...
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL. Together with its collaborators, Natera will demonstrate unmatched scale in evidence generation with 35 abstracts across molecular residual disease (MRD) testing and other innovations. Presentations w...
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT)...
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as “L-Annamycin” or “naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. Access the abstract here...
Imperial Announces Voting Results for the Election of Directors
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) reports, in accordance with the policies of the Toronto Stock Exchange, that the nominees listed in the management information circular dated April 1, 2026, were elected as directors of the Company at the Company's virtual Annual and Special Meeting of Shareholders held on May 20, 2026 (the "Meeting")...
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement demonstrated improvement in organ function, despite short follow-up First results from the Phase 1/2 LINKER-AL2 trial to be detailed in an ASCO oral presentation; the Phase 2 portion of the trial with registrational intent is ongoing TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2 trial evaluating Lynozyfic (linvoseltamab) in adults with second-line-plus systemic amyloid light chain (AL) amyloidosis, which will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting on Friday, May 29 at 2:45 p.m...
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models Data supports the broader applicability of targeting RNA splicing to attack difficult-to-treat KRAS-driven cancers
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced a poster presentation of data from the Phase 1 study of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies treated in the post-checkpoint inhibitor setting will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL...
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois...
Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash
West Palm Beach FL, May 21, 2026 (GLOBE NEWSWIRE) -- Zodiac Partners II, LLC today provided an update to its previously announced all-cash tender offer to acquire all outstanding shares of Destination XL Group, Inc. (“DXLG” or “DXL”) for $0.82 per share. After positive dialogue with shareholders representing a meaningful amount of the shares outstanding, Zodiac will shortly file an amendment to its Schedule TO elaborating on all comments...
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
NVIDIA Announces Upcoming Events for Financial Community
SANTA CLARA, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- NVIDIA will present at the following events for the financial community: TD Cowen 54th Annual Technology, Media, & Telecom Conference Thursday, May 28, at 7:15 a.m.
Navient declares second quarter common stock dividend
HERNDON, Va., May 21, 2026 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) announced that its board of directors approved a 2026 second quarter dividend of $0.16 per share on the company's common stock.
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data
Canadian Net REIT Announces 2026 First-Quarter Results and a Distribution Increase
MONTRÉAL, May 21, 2026 (GLOBE NEWSWIRE) -- Canadian Net Real Estate Investment Trust (“Canadian Net” or the “REIT”) (TSX-V: NET.UN) today reported its results for the quarter ended March 31st, 2026 (“Q1 2026”). The REIT also announced an increase in annual distributions and distributions for July, August and September 2026 (“Q3 2026”)...
Legend Biotech Announces Presentations at ASCO 2026
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including a rapid oral presentation highlighting preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC)...
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study of Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma also selected for the Plenary Session Kelonia Therapeutics, which Lilly has agreed to acquire, will present updated data for its BCMA-targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myeloma Additional Lilly presentations include the first clinical results for an investigational ADC targeting Nectin-4 in patients with advanced urothelial carcinoma and data from programs across lung, breast and blood cancers INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago, Illinois. Data at ASCO include two Plenary Session presentations, featuring primary event-free survival results from the Phase 3 LIBRETTO-432 study of adjuvant Retevmo (selpercatinib) in rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and an investigator-initiated Phase 3 study, SARC041, evaluating Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma...
WhiteFiber Signs AI Compute Agreement with Total Contract Value in Excess of $160 Million with Investment-Grade Technology Customer
NEW YORK, May 21, 2026 /PRNewswire/ -- WhiteFiber, Inc. (Nasdaq: WYFI) ("WhiteFiber" or the "Company"), a leading provider of AI infrastructure and high-performance computing solutions, today announced that it has entered into a five-year agreement to provide AI compute infrastructure for an investment-grade technology customer. The deployment will be located in the Paris region and will utilize advanced NVIDIA GPU systems...